Objective: To identify and describe clinical drug data sources that have the potential to serve as a repository of information for developing drug knowledge translation products. Methods: Two reviewers independently screened citations from PubMed and Embase, websites from the web search engine Google, and references from selected journals. Publicly licensed or non-proprietary data sources containing clinical drug information accessible in a machine-readable format were eligible. Data sources were assessed for their coverage across 18 pre-specified domains and 74 elements of clinical drug information. Results: Of the 3369 unique citations or webpages screened, 44 drug information data sources were identified. Of these, 22 data sources met the study inclusion criteria. There was a mean of 4.5 (SD ¼ 5.19) domains covered by each source and a mean of 10.9 (SD ¼ 18) elements covered by each source. None of the data sources covered all domains and eight elements were not addressed by any source. All of the data sources identified by the study are government or academic databases. Conclusion: Our study demonstrated the availability of machine-readable clinical drug data that could help facilitate the creation of novel drug knowledge translation products. However, we identified clinical content gaps in the available non-proprietary drug information sources. Further evaluation of the quality of each data source would be necessary prior to incorporating these sources into any knowledge translation products intended for clinical use.
INTRODUCTION
Information about drugs is used by patients, clinicians, and policymakers to make drug therapy decisions. In an age of rapid information development where it is approximated that by 2020 the entire body of medical knowledge will double every 73 days, 1 it is necessary to come up with novel solutions to assist with the knowledge translation of drug information. The Canadian Institutes of Health Research defines knowledge translation as "a dynamic and iterative process that includes synthesis, dissemination, exchange and ethically-sound application of knowledge to improve the health of Canadians, translation is the creation of novel knowledge translation products, which rely on repositories of knowledge. One important type of knowledge translation product is drug information tools or resources optimized to help users, be they clinicians, policymakers or patients, with the decision-making process. Drug information is a top category of information need for clinicians, and therefore drug information products are needed. 3 Clinicians have to take into account many different pieces of information, such as the patient's overall health, potential drug interactions, comparative safety and effectiveness of treatment alternatives, and concerns about factors such as adherence and cost, when deciding on a medication to treat a patient's medical condition. In order to collate the relevant data, clinicians often have to consult multiple sources of drug information, such as drug monographs and drug interaction checkers, among other sources of information. Furthermore, the nature of the visual presentation of drug information may affect knowledge transfer. One way to integrate various sources of clinical drug information and optimize human computer interactions is through building web-based knowledge translation applications. Indeed, recent technological advancements in web development allow for enhanced communication of information via dynamic web applications. Although further research in the development, dissemination, and exchange of novel knowledge translation products is needed to test this hypothesis, preliminary evidence suggests that electronic point-of-care drug information tools may enhance clinical decision making and improve patient outcomes. 4, 5 In preparation for creating and testing the effectiveness of novel web-based drug information knowledge translation products, it is important to identify available sources of drug information. The purpose of this study is to identify and examine clinical drug information sources that are publicly accessible in a machine-readable file format. We conducted a systematic assessment to identify and describe publicly available sources of clinical drug information that could potentially be used as the basis of a repository of drug information to use to build knowledge translation products.
METHODS AND ANALYSIS

Study design
We conducted a systematic assessment to identify publicly available sources of clinically oriented drug information. The protocol for the study, including exact search strings, is published in PROSPERO, the international prospective register of systematic reviews (Registration number CRD42017067456).
Search strategy
Two authors independently screened citations identified from the bibliographic databases PubMed and Embase (both from inception to May 2017) and the Internet search engine Google (search completed on May 18, 2017) to identify potential sources of clinical drug data. Of the three major web search engines (Google, Yahoo, and Bing), we chose to query Google given a previous study demonstrating it to be equal or superior to the other search engines on a number of performance evaluating tests, such as a test for precision, or the ability of the search engine to retrieve only relevant results. 6 In addition to data sources identified through bibliographic database searches and Google, we screened known drug information sources identified by the study authors, and sources identified in articles from selected health informatics journals (BMC Medical Informatics and Decision Making, Journal of the American Medical Informatics Association, Journal of Medical Internet Research, Source Code for Biology and Medicine, Methods of Information in Medicine, and the International Journal of Medical Informatics). The drug data sources identified from the articles were then screened to see if they met the study eligibility criteria.
Eligibility criteria
We included publicly available data sources pertaining to drugs used in humans and available in English. The data had to be available in a machine-readable file format and accessible either through an application programming interface (API) or as downloadable flat files.
We conceptualized 18 domains and 74 corresponding elements for the purpose of identifying and classifying the information found in each of the sources identified in the study. Domains are broad categories of clinical drug information, such as dosage/administration, indications/usage, and pharmacokinetics. The scope of information available in an identified source was determined by how many domains it covered. Elements were specific questions pertaining to each domain to assess the depth of information covered by each identified source. These were questions such as, "Is the minimum dose mentioned?" for the domain Dosage/Schedule. A complete list of all the domains and corresponding elements has been previously published in our PROSPERO protocol and is included in Supplementary Appendix A. 7 The data sources had to include at least one of the prespecified clinical elements from any domain other than the elements focused solely on indication or description of therapeutic class. We excluded drug reimbursement formularies, ontologies, and sources for which all of the clinical drug information available was obtained from another source identified by the study. We excluded data sources that pertained exclusively to natural health products, previously marketed drugs, veterinary medicinal products, physical and chemical properties, or illegal drugs. Publicly licensed proprietary data sources were excluded if their inclusion in the study or a non-commercial knowledge translation product would violate the terms of the license. Any sources that required the data to be specifically requested were excluded; however, sources that required free membership to a website in order to access the data were included.
Study selection and data extraction
Search results for PubMed, Embase, and Google, as well as references from selected health informatics journals, were imported into the open source reference-management software Zotero. Screening of articles and webpages was broken down into two levels. Level 1 was for screening of titles and abstracts from the bibliographic database searches and the initial webpages returned by the first 10 pages of results from the Google search. Level 2 was for screening of fulltext articles and full websites. In level 1 screening, abstracts identified through PubMed, Embase, and hand-screened journals were screened to identify papers that potentially mentioned drug data sources. For Google, the first page of each result returned by the searches was evaluated to see if it was a webpage of a potentially relevant data source, or if it provided links to potentially relevant data sources. In level 2 screening, full papers from relevant PubMed, Embase, and journal search results were located and screened to assess if they mentioned any relevant data sources. If a data source was mentioned in the full paper, the source was located and examined to see if it could be excluded based on any of the study criteria without any further probing (ie, writing code to examine the data). If not, the data source was moved forward for further screening. Full websites were assessed, either to see if the data sources returned did not violate study criteria or to see if links were provided to any data sources that did not violate the study criteria.
The data available from potential data sources were either parsed and interrogated using R statistical software (version 3.3.1), or the downloadable data files or API query results were evaluated to see if the information met the study criteria.
Data sources that met the study eligibility criteria were evaluated with respect to the scope and depth of information contained. We classified the scope of coverage as the number of domains covered according to 18 pre-defined drug information domains (see Table 1 ). These domains were based on a previously conducted review of online drug interaction information sources, 8 as well as consultation with two drug information pharmacists. Similarly, we classified depth of information coverage as the number of elements covered by each data source. Coverage of one element in a given domain constituted coverage of that domain. A complete list of all 18 domains and 74 elements is available in the study protocol and Supplementary Appendix A. 7 Extraction was manually completed by one reviewer assessing the data contained in downloadable files or API query results to see if the information provided by the data sources corresponded with any of our predefined domains/elements. The reviewer would assess information in the API query results or downloadable files pertaining to drugs for which answers to element questions would be expected. For example, a source with information about metronidazole would be expected to contain information about a drug-alcohol interaction pertaining to the disulfiram-like reaction experienced by individuals taking this medication when they consume alcohol. For this hypothetical example, the reviewer would look at the information the source contained pertaining to metronidazole and see if it satisfied the drug-alcohol element for the Drug Interactions domain. The rationale behind deciding if a source contained information corresponding to a particular element was annotated in the csv extraction file with random spot checks by a second reviewer.
Other information about the data sources that was recorded included the creator and maintainer of the data source, the year of initial availability, the frequency of updates, the availability of machine-readable downloadable files containing clinical drug data, the availability and type of web services, and the file type returned by any such web services. Whether the data source overlapped with any of the other data sources identified by the study was also recorded. Finally, the definition of the smallest unit of measurement (ie, drug product, active ingredient, etc.) was recorded for each database, and the number of the smallest unit of measurement was recorded. This type of information was valuable for reasons such as knowing when new information should be downloaded from a given source in keeping with its frequency of updates.
Outcomes and analysis
Our primary outcomes of interest were the proportion of clinical data domains covered by each drug information source as well as the proportion of elements covered by each source. Secondary outcomes of interest included the year of initial availability, frequency of updates, the availability and file format of any available downloadable files, the availability and type of application programming interfaces and the file format retrieved, the definition of the smallest unit of measurement (e.g. active ingredient, drug product, etc.), and the number of the smallest unit of measurement. The creator and maintainer of the data sources and whether or not the data sources overlapped with any of the others captured in the study were also recorded.
All statistical analyses were conducted using R version 3.3.1 and Microsoft Excel for Mac 2011 (Version 14.7.3). We calculated the mean number of data sources covering each domain and element. We also calculated the mean number of elements and domains covered by each data source.
RESULTS
After screening citations and webpages, we identified 44 data sources from 193 full-text articles and webpages ( Figure 1 ). The 44 sources identified were further screened, resulting in 22 data sources that met the study criteria (Table 2) . Brief descriptions of each data source, including the number of domains and elements covered by each source, are included in Supplementary Appendix B. A list of the 22 excluded data sources, including the reason for exclusion, is included in Supplementary Appendix C. None of the data sources covered all 18 clinical domains or all 74 domain elements. None of the domains was completely uncovered; however eight elements were not addressed by any source (Table 3) . A list of the sources covering each element can be found in Supplementary Appendix A. Overall, there was a mean of 5.5 (SD: 2.77) sources covering each domain and 3.24 (SD: 2.28) sources covering each element. There was a mean of 4.5 (SD: 5.19) domains covered by each source and 10.9 (SD: 18) elements covered by each source. The three domains covered most frequently were Methods of Administration, Adverse Drug Reactions, and Composition/Packaging. The most domains covered by any source was 16/18. The three sources that covered 16/ 18 domains are: AIDSinfo, DailyMed, and DrugBank.
The proportion of domains and elements covered by each source varied greatly from source to source (Figures 2 and 3) .
From Figure 3 , it can be seen that most sources cover only one domain. This is related to the academic nature of many of the data sources identified, in that the sources were designed to fill a gap in the existing knowledge.
All of the data sources identified by the study are government or academic databases. A description of the source of information for each of the data sources is included in Supplementary Appendix D. 7/22 sources were assumed or known to have information source overlap with another source identified in the study. The government databases are primarily from the United States available through the Food and Drug Administration and National Library of Medicine. The objective of many of the academic databases was to fill a gap in the clinical knowledge, eg, to provide a common repository of drug combinations or to list off-label drug side effects (DCDB and OFFSIDES, respectively). The year of initial availability of the resource (not necessarily online availability) for sources for which that information was available ranged from 1939 (Drugs@FDA) to 2012 (OFFSIDES).
There were three data sources that contained information about drugs specific to one disease category (HIV or cancer), but the majority covered a broad spectrum of clinically used drugs.
Regarding the definition of "drug" by each of the data sources, some of the sources listed drug products (eg, 10 mg ketorolac tromethamine film-coated tablets), while others listed active ingredients (eg, ketorolac). The smallest unit of measurement for the sources that listed that information varied from 22 to 93 084 "drugs" (as defined by the source). Additionally, some of the databases also covered nonclinically used drugs and other products such as disinfectants.
The frequency of updates and year of initial availability also varied greatly among different sources, and often the frequency of updates was different for different subsets of information available from the same source (eg, API updates vs. updates to downloadable files). The frequency of updates ranged from continuous updates (eg, for CIViC) to one-time publication (eg, for A Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds).
The overwhelming majority (18/22) of the databases are available in machine-readable downloadable file formats. The file formats available are tsv, csv, JSON, SQL, ASCII, and xls. 7/22 of the sources offered non-proprietary or publicly licensed REST-style (6/7), SOAP-style (1/7), or Elasticsearch-based (1/7) APIs, which returned XML, HTML, or JSON file formats. 3/22 of the sources offered both downloadable files and APIs.
DISCUSSION
This systematic assessment identified and described the scope and depth of publicly available clinical drug data sources that are available in machine-readable file formats via downloadable flat files or application programming interfaces. This work is valuable to drug information resource developers who are interested in utilizing data sources that may be readily available. The findings presented in this paper are also relevant to practitioners such as pharmacists, who are interested in expanding their knowledge of available drug information resources and the areas of information covered by each source.
Our study identified a number of diverse and overlapping clinical data sources. For example, DailyMed contains the most depth of information (55/74 elements covered) and covers high-importance drug data domains in great detail, such as Dosage/Schedule, Drug Interactions, and Adverse Drug Reactions (see Figure 2 ). DailyMed covers a large breadth of drugs used to treat many diseases and is therefore one of the most valuable databases to help construct a drug information repository for the purpose of creating knowledge translation products.
It is important to note that information that was available for some drugs in a database, such as absorption, distribution, metabolism, and excretion data for the IDA2PM data source, was not necessarily available for every drug listed in the source. Thus, gaps of information may need to be filled for individual drugs. Further examination of the information available for each drug included in each of the identified sources would be necessary to fully understand this gap in the identified information. AIDSinfo demonstrated an excellent depth and scope of information for the drugs it contained (see Figures 2  and 3 ), but it is important to keep in mind that this data source contains drugs pertaining only to the treatment of HIV/AIDS, and thus has limitations in the breadth of drugs covered. This is an important consideration for further evaluating and understanding gaps that may exist in the retrieved information sources for non-HIV/AIDS drugs.
The results of our study suggest that it would be valuable to develop data sources to fill the information gap for certain defined elements that were not addressed by any sources identified in this study. For example, information pertaining to off-label drug usage was consistently missing from many of the sources. Information regarding the use of diagnostic tests, toxicity, compatibility and storage, the mechanism of action for drug interactions (eg, CYP3A4 inhibition resulting in reduced metabolism), and occupational hazard warnings (eg, caution about performing tasks requiring mental alertness such as operating machinery or driving) were also missing. While certain information such as approved indications would be essential information for a drug therapy knowledge translation product, off-label indications could be added via a manual curation process as information, such as that from individual randomized controlled trials, becomes available.
There are several limitations that must be considered when interpreting our study findings. First, it is important to acknowledge that the objective of this review was to identify data sources and describe the information contained in the data sources for the purpose of identifying gaps that may need to be filled by other sources in order to have complete drug information for use in a drug knowledge translation product (in addition to manually curated information pertaining to individual studies, etc., as that information becomes available). Therefore, we did not assess the accuracy of each data source. However, we did ensure that the data sources described their source content and that there were no red flags for inappropriate source content. We did not compare the identified data sources to a "gold standard" of information, nor did we critically appraise the quality of the information in each source using a standardized tool, as this was beyond the scope of this paper. To our knowledge, a validated tool for assessing the quality and accuracy of drug information does not exist. A brief description of the content sources of each of the identified data sources is included in Supplementary Appendix D. A quality and accuracy appraisal of the information identified in the data sources would have to be done prior to incorporating the information into any knowledge translation products. This would likely involve a concerted effort to critically appraise the data sources as a whole and the methods of information retrieval of each of the sources, along with critical appraisal of the information for individual drugs by healthcare professionals.
Second, the information in each of the identified data sources was extremely heterogeneous in terms of information structure (eg, therapeutic class was a category of information for some data sources vs. being mentioned in a paragraph regarding mechanism of action for other sources) and data formats. This presented a challenge for the purpose of data extraction and comparison among clinical data sources. However, the data extraction file was annotated to describe exactly where each piece of information was found in a given database to lessen the difficulty of this challenge for the next phase of work.
Third, in order to assess whether a source contained information pertaining to an element question, drugs for which information answering those element questions is known to exist were chosen and evaluated in the data source (detailed in the Methods section). This approach was dependent on the drug chosen and therefore may have resulted in missing elements for a drug that was not searched. Furthermore, it was impossible to choose the same drugs for each source to assess coverage of certain elements, as certain sources included only information for a specific group of drugs (eg, chemotherapeutic agents). A list of drugs searched for each data source for which information pertaining to our elements was found is available in Supplementary Appendix E.
Fourth, the domains and elements used to assess the scope and depth of information coverage by the sources were not externally validated. However, our intention was not to compare the validity of the information in the data sources but rather to describe their content. Our list of domains and elements was developed for this purpose in consideration of the needs of users of drug information and in consultation with two drug information pharmacists. It is possible that there are other relevant elements that we did not consider. The severity of drug interactions was an element of drug information that we did not evaluate. Although an essential aspect of drug interactions, the severity of drug interactions is a difficult topic that is often incorrectly assessed. 31 Fifth, it could be argued that it would be necessary to include only the databases that contained the greatest coverage of elements for a particular domain for use in the creation of any novel drug knowledge translation products. However, limitations to the study design resulted in some of the differences between databases being inadequately captured. For example, DCDB offers information on synergistic drug combinations, which was not captured by the study but is incredibly useful information clinically. Another example is the OFFSIDES database, which lists off-label drug adverse effects. The information in this data source could be useful for a clinician faced with a patient experiencing a rare adverse effect to a drug for which there are no documented case reports but for which there is some existing evidence in OFFSIDES of the adverse effect. However, due to the limitations of our data extraction method, OFFSIDES covers only one domain (Adverse Effects) and one element in that domain, which on initial examination could make it seem equivalent to SIDER, which lists drug adverse effects found on public documents and package inserts. However, these two data sources contain very different pieces of information. Further exploration of the data would be necessary to truly understand the differences in the information provided in order not to overload a data repository with redundant information, but also to ensure important differences in the information provided by the data sources are not missed.
Sixth, some of the data sources identified have restrictions in their usability for resource developers, particularly regarding their ability to be used for commercial purposes without purchasing a license.
Finally, some of the data sources initially identified contained information that was tremendously valuable but was not captured in our domains and elements. For example, TWOSIDES database, 21 a database similar to the OFFSIDES database and also produced by the Tatonetti Lab at Columbia University, provides information about polypharmacy side effects for drug pairs. Since this data source did not satisfy our study criteria, the information was not captured. Another example is the Stanford HIV drug-resistance database, 32 which is currently used by clinicians treating patients with HIV, but the information was not captured by our study.
CONCLUSION
In conclusion, the results of our study demonstrate that many clinical drug data sources exist, which cover many clinical data domains and corresponding elements that may be useful in constructing a drug information repository to build novel drug information tools. Further qualitative studies may be necessary to further evaluate the known and unexplored gaps in the type of information required to be able to optimally construct a drug information repository. For example, to develop a better understanding of the desired needs of clinicians and patients prior to the construction of any dynamic web applications designed to aid in drug therapy decision making. Once built, the knowledge translation products themselves will need to be tested for usability (eg, efficiency) in the clinical setting compared with standard sources of information.
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